Can We Use DAPT for 3 Months in Acute Coronary Syndrome?

Current guidelines recommend 12-month dual antiplatelet therapy (DAPT) after DES stenting for acute coronary syndrome (ACS) because of elevated MACE risk. 

¿Podemos utilizar DAPT durante 3 meses en síndromes coronarios agudos?

The development of more modern stents, with thin and ultrathin struts, compared against prior versions, has resulted in more effective devices in terms of stent thrombosis and restenosis. 

Prolonged DAPT has been associated with more bleeding, especially digestive. 

At present, there is evidence (from randomized studies and registries) to support the use of short term DAPT (1-3 months) to reduce bleeding. However, it has not yet been adopted after DES stenting for both acute and chronic coronary syndrome. 

This meta-analysis included 5 randomized studies (REDUCE, RESET‐ACS, SMART‐CHOICE, TICO and TWILIGHT‐ACS) with a total 16781 patients. 8387 receiving 3-month DAPT (49.97%) and receiving 8394 12-month DAPT.

Read also: Invasive Myocardial Viability Indexes.

The groups were similar.

There were no differences between the strategies in MACE (RR: 0.92; 95% CI: 0.76–1.11), cardiovascular mortality (RR: 1.26; 95% CI: 0.38–4.17), all-cause mortality (RR: 0.92; 95% CI: 0.48–1.77), MI (RR: 0.98; 95% CI: 0.74–1.30) or stent thrombosis (RR: 1.30; 95% CI: 0.55–3.05).

3-month DAPT presented a significant reduction of major bleeding vs 12-month DAPT (RR: 0.53; 95% CI: 0.43–0.64).

Conclusion

In ACS patients undergoing DES stenting, 3-month DAPT reduces bleeding risk with no increase of other complications. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Original Title: Three versus 12‐month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta‐analysis of randomized controlled trials.

Reference: Vijairam Selvaraj, et al. Catheter Cardiovasc Interv. 2022;100:1151–1158.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...